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SUMMARY
Introduction: The Clinical and Laboratory Standards Institute (CLSI)
has produced a guideline detailing how to determine the activated
partial thromboplastin time’s (APTT) sensitivity to clotting factor
deficiencies, by mixing normal and deficient plasmas. Using the
guideline, we determined the factor sensitivity of two APTT reagents.
Methods: APTTs were performed using Actin FS and Actin FSL on a
Sysmex CS-5100 analyser. The quality of factor-deficient and refer-
ence plasmas from three commercial sources was assessed by assay-
ing each of the clotting factors within the plasmas and by
performing thrombin generation tests (TGT).
Results: Testing samples from 50 normal healthy subjects gave a
two-standard deviation range of 21.8–29.2 s for Actin FS and 23.5–
29.3 s for Actin FSL. The upper limits of these ranges were subse-
quently used to determine APTT factor sensitivity. Assay of factor
levels within the deficient plasmas demonstrated that they were
specifically deficient in a single factor, with most other factors in
the range 50–150 iu/dL (Technoclone factor VII-deficient plasma
has 26 iu/dL factor IX). APTTs performed on mixtures of normal
and deficient plasmas gave diverse sensitivity to factor deficiencies
dependent on the sources of deficient plasma. TGT studies on the
deficient plasmas revealed that the potential to generate thrombin
was not solely associated with the levels of their component
clotting factors.
Conclusion: Determination of APTT factor sensitivity in accordance
with the CLSI guideline can give inconsistent and misleading results.
INTRODUCTION
The activated partial thromboplastin time (APTT) is a
central component of any screen for haemostatic
patency. The test is used to detect the deficiency of
intrinsic clotting factors (VIII, IX, XI, or XII), the
presence of lupus anticoagulant and the monitoring of
unfractionated heparin therapy, although this latter
function is becoming less common in many countries
as unfractionated heparin has to a large extent been
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replaced with low molecular weight heparin. Conse-
quently, the major role of the APTT at many centres
is now detection of clotting factor deficiencies either
in the form of a preoperative clotting screen or in
patients who present with a history of a haemorrhagic
diathesis. However, APTT reagents show different
sensitivities to deficiencies of factors VIII, IX, XI and
XII; this is thought to be because of differences in the
activator or phospholipids used in the reagent [1,2].
Using samples from patients with congenital clot-
ting factor deficiencies, we have previously assessed
the sensitivity of two widely used APTT reagents,
Actin FS and Actin FSL (Siemens Healthcare Diagnos-
tics, Marburg, Germany) [3]. Collection of clinical
samples from patients with a single congenital coagu-
lation factor deficiency (factors VIII, IX, XI or XII defi-
cient) at appropriate levels of activity (i.e. 10–50%)
taken into the sample tubes employed in a specific
institute for a study of this type presents a logistical
problem that would be beyond the capabilities of
many general hospitals. Consequently, the Clinical
and Laboratory Standards Institute (CLSI) Guideline
[4] offers an alternative means of assessing APTT’s
sensitivity to clotting factor deficiencies, which claims
to circumvent this logistical problem.
The Guideline [4] requires that APTTs are
performed on factor-deficient plasmas (i.e. factors VIII,
IX, XI and XII) to which normal control plasma is
added to give a range of relative potencies (<1 to
100%) for factors VIII, IX, XI and XII. However, as
the APTT is a global test, the resultant clotting times
would be influenced by the levels of all clotting
factors within the spiked deficient plasma, not just the
level of the clotting factor that had been adjusted. To
investigate the influence of the factor-deficient plasma
and normal plasma used, we determined the sensitiv-
ity of Actin FS and Actin FSL using three sources of
plasma. The quality of factor-deficient plasma was also
assessed in a thrombin generation test [5].
SAMPLES AND METHODS
Unless otherwise stated, all tests were performed on a
Sysmex CS-5100 analyser (Sysmex UK Ltd, Milton
Keynes, UK), and reagents were from Siemens
Healthcare Diagnostics (Marburg, Germany). In addi-
tion to normal reference plasma and factor-deficient
plasma from Siemens, lyophilized factor-deficient and
reference plasmas were also obtained from Techno-
clone (Vienna, Austria). Frozen reference and factor-
deficient plasmas (CryocheckTM) were obtained from
Precision BioLogic (Nova Scotia, Canada).
Normal reference ranges for the two APTT
reagents, Actin FS and Actin FSL, were confirmed
using plasma samples from 50 healthy normal individ-
uals. APTT quality control imprecision studies, using
Actin FS and Actin FSL, were performed using
commercial lyophilized normal (Control Plasma N
[CPN]) and pathologically low plasmas (Control
Plasma P [CPP] and CiTrol 2). Ten replicates of each
preparation were tested on each of 5 days.
Factor assays were performed using either Actin
FS (for factors VIII, IX, XI and XII) or Innovin (for
factors II, V, VII and X). Fibrinogen concentration
was measured using the Clauss technique. Levels of
the component clotting factors within the Siemens,
Technoclone and CryocheckTM factor-deficient plas-
mas were determined relative to the Siemens refer-
ence preparation (Standard Human Plasma [SHP]).
Similarly, the levels of clotting factors within the
Technoclone and CryocheckTM Reference plasmas
were assayed relative to the SHP. The factor assays
were all performed with samples tested at multiple
dilutions, which facilitated an assessment of linearity
and parallelism of dose response and thus detect
possible inhibitory activity or falsely high results
caused by sample activation [6].
The sensitivity of APTT reagents to coagulation
factor deficiency was assessed using factor-deficient
Table 1. APTT imprecision using three levels of commercial quality control plasma
Reagents
Control Plasma N Ci-Trol Level 2 Control Plasma P
Mean (s) SD (s) CV (%) Mean (s) SD (s) CV (%) Mean (s) SD (s) CV (%)
Actin FS 26.1 0.12 0.48 44.8 0.23 0.50 51.3 0.68 1.33
Actin FSL 26.2 0.09 0.36 42.3 0.22 0.51 74.7 1.51 2.03
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plasmas spiked with normal plasma to give samples
with 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%
and 10% activity of the single factor. For this process,
Siemens deficient plasmas (factors VIII, IX, XI and XII)
were spiked with Siemens SHP, Technoclone deficient
plasmas with Technoclone Coagulation Reference
Plasma and CryocheckTM deficient plasmas with
CryocheckTM normal reference plasma. Each of the
spiked plasma samples was assayed to confirm the
activity of the single factor.
Thrombin generation test (TGT) studies were per-
formed on the factors VIII-, IX-, XI- and XII-deficient
plasma using the calibrated automated thrombogram
(CAT) system as described by Hemker et al. [5]
(Thrombinoscope BV, Maastricht, the Netherlands) in
conjunction with the manufacturer’s PPP-low
reagents, which gives a reaction concentrations of
1 pM tissue factor (TF)/4 lM phospholipid (PL)
(Thrombinoscope BV). The thrombin generation test
(TGT) provides information relating to the dynamics of
thrombin generation (TG), and the TG curve is
described in terms of the lag time, the time to peak,
peak thrombin and the area under the TG curve,
known also as the endogenous thrombin potential
(ETP).
RESULTS
The normal reference ranges for APTTs performed
using Actin FS and Actin FSL were confirmed by
Table 2. Levels of coagulation factors in commercial deficient plasmas
Def Plasma
Fg
(g/L)
FII
(iu/dL)
FV
(iu/dL)
FVII
(iu/dL)
FVIII
(iu/dL)
FIX
(iu/dL)
FX
(iu/dL)
FXI
(iu/dL)
FXII
(iu/dL)
Technoclone
FII 2.75 <1.0 92 125 79 105 104 77 102
FV 3.31 109 <1.0 106 72 124 116 99 115
FVII 2.88 109 91 <1.0 83 26 103 83 102
FVIII 2.18 96 89 126 <1.0 98 105 50 63
FIX 3.14 85 123 72 100 <1.0 107 67 98
FX 2.44 102 80 109 106 84 <1.0 61 113
FXI 2.34 115 111 138 82 92 91 <1.0 73
FXII 2.31 95 91 122 92 112 96 82 <1.0
Ref Plasma 2.75 98 93 114 98 111 99 87 93
Siemens
FII 2.15 <1.0 92 97 74 79 89 74 93
FV 1.90 82 <1.0 85 70 76 84 76 85
FVII 2.13 82 86 <1.0 78 78 80 76 83
FVIII 1.95 78 81 85 <1.0 74 80 67 55
FIX 2.34 90 103 102 68 <1.0 98 83 86
FX 2.44 94 95 103 74 92 <1.0 84 95
FXI 1.99 84 91 86 73 77 88 <1.0 84
FXII 2.37 97 97 105 80 93 99 82 <1.0
Ref Plasma 2.48 94 87 94 90 93 92 88 98
CryoCheck
FII 2.18 <1.0 92 117 95 116 114 94 110
FV 2.84 110 <1.0 123 110 123 120 102 113
FVII 2.84 109 103 <1.0 105 118 114 102 116
FVIII 2.13 117 106 137 <1.0 130 126 111 107
FIX 2.84 111 106 131 105 <1.0 127 97 116
FX 2.75 108 88 124 96 110 <1.0 90 112
FXI 2.93 109 114 115 106 115 122 <1.0 107
FXII 2.75 112 79 144 103 123 123 99 <1.0
Ref Plasma 2.63 112 120 123 109 123 123 104 107
The highlighted coagulation factor levels are either equivocal or below the normal reference range.
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testing the plasma from 50 healthy normal individu-
als. This process gave a mean  two-standard devia-
tion range of 21.8–29.2 s for Actin FS and 23.5–29.3 s
for Actin FSL. The upper limits of these ranges were
subsequently used to determine APTT factor sensitiv-
ity. Reproducibility of the APTT assessed using
commercial lyophilized normal and pathologically low
plasmas yielded similarly low levels of imprecision for
both Actin FS and Actin FSL (Table 1).
Factor assays performed to assess the levels of the
component clotting factors within the Siemens,
Technoclone and CryocheckTM factor-deficient plasmas
confirmed normal activity (50–150 iu/dL) of each of
the clotting factors present (Table 2). Only one of the
deficient plasmas was found to have an equivocal
level of a relevant clotting factor (Technoclone factor
VIII-deficient plasma, factor XI level 50 iu/dL)
(Table 2).
Using the upper limit of the APTT reference
ranges, the sensitivity of APTT reagents to a single
coagulation factor deficiency was determined with
factor-deficient plasma spiked with normal plasma to
give samples of 90%, 80%, 70%, 60%, 50%, 40%,
30%, 20% and 10% activity (an example of which
is seen in Figure 1). Data from this study demon-
strated that APTT’s sensitivity to clotting factor defi-
ciency was influenced by the source of deficient and
normal reference plasma used (Table 3). Thrombin
generation studies revealed that the potential to
generate thrombin was not solely related to the
levels of clotting factors present in the deficient
plasma (Figure 2).
DISCUSSION
Central to the role of the APTT is an understanding of
its ability to detect clotting factor deficiencies. As the
APTT is a global clotting test, a normal APTT does not
necessarily indicate that all clotting factors within the
intrinsic coagulation pathway (factors VIII, IX, XI and
XII) are normal. A deficiency of one intrinsic clotting
factor can be masked by an elevated level of another.
For example, FVIII elevated by an acute phase
response can mask a mild or even moderate
deficiency of factor IX or XI. For this reason, when
defining the sensitivity of an APTT reagent to a single-
factor deficiency, it is essential to determine the qual-
ity of the samples used for this process by measuring
Table 3. Level of intrinsic clotting factor detected at
Upper Limit of APTT
Deficient
Plasma
APTT Upper Limit
(s)
Actin FS Actin FSL
29.2 29.3
Technoclone F. VIII Activity
(%)
68 66
Siemens 73 62
CryoCheck 32 32
Technoclone F. IX Activity
(%)
58 46
Siemens 76 56
CryoCheck 32 25
Technoclone F. XI Activity
(%)
58 46
Siemens 71 50
CryoCheck 52 25
Technoclone F. XII Activity
(%)
22 22
Siemens 78 50
CryoCheck 14 18
F VIII F IX F XI F XII
Cut-Off 31% 31% 52% 14%
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Figure 1. Determination of Actin
FS Factor Sensitivity using
CryoCheck Frozen Factor-
Deficient Plasma.
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all intrinsic clotting factors in the samples and the
precision with which the instrumentation measures
the APTT.
Our imprecision data (Table 1) demonstrated
highly reproducible APTTs at the three levels of qual-
ity control with both the Actin FS and Actin FSL
reagents. Importantly, we also demonstrated that each
of the factor-deficient plasmas used in the study was
specifically deficient in a single clotting factor while
the other component clotting factors were present at
normal levels (50–150 iu/dL), as shown in Table 2.
Consequently, when the deficient plasmas were
spiked with normal plasmas to yield a range of rela-
tive potencies, as suggested by the CSLI guideline [4],
it was interesting to observe the wide range of clotting
factor activities that were associated with the APTT
upper limit of the normal reference range using Actin
FS and Actin FSL (Table 3).
As would be anticipated, when TGT studies were
performed using a TF trigger, the FXII-deficient plas-
mas gave a normal thrombin generation (TG) curve
while the FX-, FVII-, FV- and FII-deficient plasmas
gave no TG under the test conditions described (data
not shown). However, the FVIII- and FIX-deficient
plasma TGT results were intriguing because those
plasmas with the highest levels of component clotting
factors (i.e. CryocheckTM, frozen plasma) gave the low-
est level of TG while the plasma with the lowest levels
of clotting factors (i.e. Siemens, lyophilized plasma)
gave the highest level of TG. This suggested that the
potential to generate thrombin was not solely associ-
ated with the level of component clotting factors; it
Factor VIII deϐicient plasma Factor IX deϐicient plasma
Group name Reference
Plasma
FVIII
(CC)
FVIII
(TC)
FVIII
(S)
FIX
(CC)
FIX
(TC)
FIX
(S)
Lag time
(minutes) 7.5 7.3 7.8 6.8 8.0 8.5 7.0
ETP (nM) 1720 616 988 1161 569 1020 704
Peak (nM) 189 17 43 66 16 38 25
Time to Peak
(minutes) 12.5 16.5 18.5 13.0 17.3 18.7 14.3
% ETP 100 35.8 57.4 67.5 33.1 59.3 40.9
% Peak 100 9.2 22.5 35.2 8.7 20.0 13.5
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Figure 2. Thrombin generation curves for FVIII- and FIX-deficient plasmas – 1 pM TF. CC: Cryocheck, TC:
Technoclone, S: Siemens. ETP: Endogenous thrombin potential. % ETP and % Peak were calculated by expressing
the specific activity of these parameters as percentage of the normal reference plasma processed in the same assay.
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could be speculated that lyophilized deficient plasmas
may contain a procoagulant material [7] that only
exerts an effect in TGT or in a test system such as that
described in the CSLI guideline [4]. This does not
mean lyophilized plasmas are unsuitable for their
intended use (i.e. one-stage clotting assays), as each of
the deficient plasmas produced sensitive dose–
response curves in one-stage clotting assays.
We conclude that determination of APTT factor
sensitivity performed in accordance with CLSI Docu-
ment H47-A2 [4] can give inconsistent and mislead-
ing results, and this approach should not be used in
routine laboratory practice. Consequently, detection
limits should either be determined by the reagent
manufacturers for specific instrument/reagent
systems or by individual laboratories using well-
characterized samples from patients with inherited
coagulation deficiencies. We would suggest testing a
minimum of 20 deficient samples with potencies
evenly distributed in the range 10–50% for each of
the intrinsic coagulation factors (factors VIII, IX, XI
and XII).
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